-
Seeds Rybakina, Pegula, Gauff reach third round at WTA Toronto
-
Messi scores twice to set Leagues Cup record in Miami victory
-
Police raid South Korea FA in probe into World Cup coach appointment
-
Asian stocks mostly down with tech firms back under pressure
-
Low water on Germany's Rhine river threatens new blow to economy
-
Back to the future as world champion Springboks host All Blacks
-
Ex-Wallabies Foley, Phipps rejoin Waratahs ahead of home World Cup
-
India youth protests highlight mistrust in 'lapdog' media
-
Rising Kenyan lakes push crocodiles closer to homes
-
Pacific islands alarmed by Trump-backed push for deep-sea mining
-
Istanbul cymbals: From Ottoman war tool to pulse of global music
-
Erratic rains dictate menu at three-star Michelin restaurant in Brazil
-
Myanmar ex-junta chief on first Thailand trip as civilian leader
-
Zverev, Auger-Aliassime and Medvedev exit Montreal Masters
-
Environmental disaster looms as tanker leaks off Oman
-
Google-parent Alphabet shakes up AI division
-
Embattled Infantino sees minnows Malawi reach WAFCON quarter-finals
-
FIFA back Infantino, apologise for World Cup privatisation plan
-
Seeds Rybakina, Pegula and Gauff advance at WTA Toronto event
-
Auger-Aliassime out of Montreal ATP event with injury
-
Zverev, Auger-Aliassime exit star-short Montreal Masters
-
Colombian baby hippo of Escobar stock dies after rescue
-
Embattled FIFA chief Infantino in emergency talks in Morocco
-
Preakness shifts 2027 dates to entice more Derby horses
-
Castaway SpaceX rocket stage crashed into Moon, scientists say
-
Guatemalan volcano eruption ends, locals return home
-
Dow edges to record as markets parse prospects for Hormuz deal
-
WHO chief urges stronger Ebola response in DR Congo visit
-
Salah arrives in Turkey to complete Trabzonspor move
-
Newcastle appoint Jaissle as new head coach after Howe exit
-
AFP journalist to be honored at International Press Freedom Awards
-
Swiss ski star Lara Gut-Behrami calls time on 18-year career
-
Turkish MPs back limited amnesty for Kurdish militants
-
US indicts leaders of Mexico's CJNG cartel, ups reward money
-
Noosha Aubel: Czy poradzi sobie z problemami Poczdamu?
-
Noosha Aubel: Είναι σε θέση να αντιμετωπίσει τα προβλήματα του Πότσδαμ;
-
Noosha Aubel: Klarar hon av Potsdams problem?
-
Noosha Aubel: Zvládne problémy Postupimi?
-
نوشا أوبيل: هل هي على مستوى التحديات التي تواجهها بوتسدام؟
-
Former England fly-half Burns retires from rugby union
-
Brazil hits new diplomatic lows with US and Argentina
-
Pakistan beat West Indies by eight wickets to level series
-
NZ boxer Parker promises ring return after doping ban 'lifted'
-
Reusser holds lead as Vollering wins in Tour de France hills
-
Disney profits top estimates on strength in theme park business
-
Argentina's Albornoz hit with four-game ban for 'intimidatory' referee abuse
-
LIV Golf CEO says funding secured to play beyond 2026
-
Guatemala volcano eruption eases off, but alert remains in place
-
Stocks stall tracking earnings, oil dips on Iran-Oman Hormuz move
-
Baby hippo descended from Escobar's herd rescued in Colombia
Biden proposes huge expansion of weight loss drug access
Outgoing US President Joe Biden proposed Tuesday to give millions more Americans access to weight loss drugs -- but Donald Trump's incoming health chief looked set to shoot down the idea.
Under the massive US public health insurance programs Medicare and Medicaid, drugs like Ozempic and Wegovy are, for the most part, only available for overweight people with diabetes or heart disease.
But the White House said Biden wanted to make the game-changing medications widely available as a treatment for obesity itself -- expanding coverage to nearly 7.5 million older and lower-income Americans.
"For too many Americans, these critical treatments are too expensive and therefore out of reach," a White House official said, noting that 42 percent of Americans are obese.
The Department of Health and Human Services said separately in a statement that the "transformative medications" would improve the "health and quality of life for millions of people who have obesity."
The move would benefit 3.4 million Americans with Medicare, which gives health insurance to people mainly aged over 65. It would also help four million people eligible for assistance with Medicaid, which targets lower income residents, officials said.
But the last-gasp plan appears unlikely to survive given that Trump's incoming health secretary, Robert F. Kennedy Jr., has previously spoken out against the use of anti-obesity drugs.
In October Kennedy opposed a separate bill in Congress that would have expanded access to the medications, saying the money needed to do that would be better spent on improving nutrition.
"If we spent about one fifth of that giving good food, three meals a day to every man, woman and child in our country, we could solve the obesity and diabetes epidemic overnight," Kennedy said on Fox News.
- 'So stupid' -
He also accused the Danish makers of Ozempic and Wegovy, Novo Nordisk, of "counting on selling it to Americans, because we're so stupid and addicted to drugs."
Kennedy has attracted major controversy for his anti-vaccine activism and embrace of conspiracy theories -- but some of his proposals for improving American's diets have won praise from health campaigners and lawmakers.
Any plan to increase US public health insurance spending would also likely run foul of Trump's bid to slash government budgets and waste.
Trump said last week as he appointed celebrity TV doctor Mehmet Oz to head Medicare and Medicaid that Oz would "cut waste and fraud" in what he called "our Country's most expensive Government Agency."
The Republican has also named tech tycoon Elon Musk and entrepreneur Vivek Ramaswamy to head a so called "government efficiency" commission to cut costs across government.
Biden has taken a different tack during his sole term in office.
The Democrat has led a major drive to lower the exorbitant cost of US prescription medicines, and his success in forcing pharmaceutical giants to reduce the prices of some became a key plank of his reelection campaign before he dropped out in July.
In July, Biden called on Novo Nordisk and Eli Lilly to lower prices for diabetes and weight loss drugs, saying firms must stop "ripping off the American people."
F.Santana--PC